Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
ABL Bio
company
About
It is based on developing bispecific antibody cancer programs.
- 51 - 100
Highlights
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- ₩20B
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2016
- Number Of Employee
- 51 - 100
- Operating Status
- Active
ABL Bio is one of the world's leading biotech research companies focusing on the development of therapeutic drugs for immuno-oncology & neurodegenerative diseases. Their core values are life-improvement, collaboration, innovation and novel therapy.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
₩29B
ABL Bio has raised a total of
₩29B
in funding over 2 rounds. Their latest funding was raised on
Mar 31, 2017 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 31, 2017 | Series B | ₩20B | 2 | — | — | Detail |
| Jul 19, 2016 | Series A | ₩9B | 1 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
3
ABL Bio is funded by 3 investors.
HantuPa
and Global Bio Growth First Private Equity Investment
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series A |
|
|
— | Series B |
|
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
